RESUMO
The results of a prospective trial of an 8 week treatment for elderly patients with advanced intermediate-high grade NHL are reported. Our aim was to reduce general toxicity without losing an antilymphoma effect. For this reason the use of growth factor was studied. We also analysed the behavior of different histological groups (E + F vs G + H). From November 1991 to November 1993 100 patients older than 65 years with combination intermediate-high grade advanced stage NHL were treated with the P-VEBEC regimen, an original including epirubicin 50 mg/sqm, cyclophosphamide 300 mg/sqm and etoposide 100 mg/sqm on weeks 1, 3, 5, 7; vinblastine 5 mg/sqm and bleomycin 5 mg/sqm on weeks 2, 4, 6, 8; prednisone 50 mg/sqm/day per os in the first two weeks and thereafter every other day .46 pts received rG-CSF 5 micrograms/Kg/day throughout the treatment starting on day 2 of every week for 4 consecutive days. Twenty eight pts had B symptoms, 41 had bulky disease, 37 LDH levels above normal, 50 stage IV patients and 30 had bone marrow involvement. Sixty two percent achieved a complete remission (CR). Adverse prognostic factors for CR were E and F histology, stage IV disease, bone marrow infiltration, serum LDH levels above normal, international Prognostic Index (I.I.) intermediate-high and high risk categories and relative dose intensity (RDI) less than 0.80. Severe toxicity was rarely recorded and only one toxic death was observed. With a median follow-up of 33 months OS, DFS and EFS were 44%, 60% and 30% respectively. EFS was influenced by stage, BM involvement, level of LDH and I.I. intermediate-high and high risks. The 52 patients with DLCL (diffuse large cell lymphomas--G + H according to WF) did better with a higher CR, OS, DFS and EFS rates, than the other WF subtypes. In conclusion P-VEBEC is a feasible combination to use in elderly patients, mainly in DLCL. The use of rG-CSF improves the RDI. A RDI > 0.80 could play a role in improving the outcome, especially in patients with adverse prognostic factors. For other subgroups another schedule is probably justified.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/tratamento farmacológico , Idoso , Anti-Infecciosos/uso terapêutico , Antibioticoprofilaxia , Antifúngicos/uso terapêutico , Infecções Bacterianas/prevenção & controle , Bleomicina/administração & dosagem , Medula Óssea/patologia , Ciclofosfamida/administração & dosagem , Intervalo Livre de Doença , Esquema de Medicação , Epirubicina/administração & dosagem , Etoposídeo/administração & dosagem , Estudos de Viabilidade , Feminino , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Cetoconazol/uso terapêutico , Linfoma não Hodgkin/mortalidade , Linfoma não Hodgkin/patologia , Masculino , Micoses/prevenção & controle , Estadiamento de Neoplasias , Ofloxacino/uso terapêutico , Prednisona/administração & dosagem , Prognóstico , Estudos Prospectivos , Proteínas Recombinantes/uso terapêutico , Taxa de Sobrevida , Vimblastina/administração & dosagemRESUMO
BACKGROUND: The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute risk of acute and delayed emesis following cisplatin by 20 and 30%, respectively. OBJECTIVE: To measure the value that patients with cancer place on improved emesis control and quality of life. DESIGN: Willingness-to-pay analysis. SETTING: Five study sites in Canada, Italy, Spain and Greece. PATIENTS AND PARTICIPANTS: 245 patients with cancer either receiving chemotherapy with cisplatin or who had received cisplatin-based chemotherapy within the previous 6 months. METHODS: After background information had been presented, patients were asked to define the maximum that they would pay per day for a drug that reduced their risk of acute and delayed (days 2 to 5) emesis by 20 and 30%, respectively. Costs were converted to US dollars ($US) using year 2000 exchange rates. RESULTS: For a 20% improvement in acute emesis, Canadian, Italian and Spanish patients with cancer were willing to pay $US46, $US34 and $US63 per day, respectively, compared with $US8 for patients from Greece (p < 0.001). For a 30% improvement in delayed emesis, Canadian, Italian and Spanish patients with cancer were also willing to pay more than their Greek counterparts (SUS41, $US31, $US50 and $US9 daily for 4 days, respectively; p < 0.001). These significant differences in patient value between countries remained, even after adjusting for socioeconomic variables and previous history of emesis. CONCLUSIONS: There are substantial cultural differences in how patients with cancer value benefit and improved quality of life. Since the majority of the world's population resides outside North America and Western Europe, there may be a need to re-evaluate perceived levels of patient benefit and measures of quality of life.
Assuntos
Antieméticos/economia , Antineoplásicos/efeitos adversos , Cisplatino/efeitos adversos , Neoplasias/tratamento farmacológico , Qualidade de Vida , Vômito/prevenção & controle , Antieméticos/uso terapêutico , Antineoplásicos/uso terapêutico , Atitude Frente a Saúde , Canadá , Cisplatino/uso terapêutico , Europa (Continente) , Feminino , Humanos , Renda , Masculino , Pessoa de Meia-Idade , Vômito/induzido quimicamenteAssuntos
Antibióticos Antineoplásicos/efeitos adversos , Epirubicina/efeitos adversos , Coração/efeitos dos fármacos , Disfunção Ventricular Esquerda/induzido quimicamente , Antibióticos Antineoplásicos/uso terapêutico , Neoplasias da Mama/sangue , Neoplasias da Mama/tratamento farmacológico , Epirubicina/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/sangue , Estudos Prospectivos , Ventriculografia com Radionuclídeos , Ultrassonografia , Disfunção Ventricular Esquerda/sangue , Disfunção Ventricular Esquerda/diagnóstico por imagemRESUMO
We compared two different methods of collecting endocervical samples for examination by direct immunofluorescence for Chlamydia trachomatis. A cervical Cytobrush gave better results than a dacron swab. Further studies should be performed to assess the value of alternative sampling methods to detect this organism.
Assuntos
Colo do Útero/microbiologia , Chlamydia trachomatis/isolamento & purificação , Manejo de Espécimes/instrumentação , Adolescente , Adulto , Feminino , Imunofluorescência , HumanosRESUMO
The direct immunofluorescence assay (DFA) was compared with culture for test-of-cure analysis for Chlamydia trachomatis in patients 7 to 10 days after antimicrobial therapy was given. DFA test-of-cure results correlated with culture results in 79.5% of 39 patients. Of DFA-negative patients, 97% had negative cultures. Six of seven patients with borderline DFA results had negative culture results.
Assuntos
Infecções por Chlamydia/diagnóstico , Chlamydia trachomatis/isolamento & purificação , Doenças dos Genitais Femininos/diagnóstico , Adolescente , Adulto , Infecções por Chlamydia/tratamento farmacológico , Feminino , Imunofluorescência , Doenças dos Genitais Femininos/tratamento farmacológico , Humanos , Valor Preditivo dos TestesRESUMO
DNA synthesis time (Ts) and 3H thymidine (TdR) labelling index (LI) of bone marrow (BM) myelomatous plasma cells (PC) and of the residual haemopoietic cell population (RHCP) were measured by in vitro quantitative 14C-TdR autoradiography in five patients with multiple myeloma (MM) in different phases of disease (three at presentation and two at relapse) and in one patient with solitary extra-osseous myeloma. One other patient with plasma cell leukaemia (PCL) was studied during an initial relapse phase and later during the leukaemic terminal phase. PC Ts was 18.8 +/- 3.7 (from 13.3 to 25.0) hr and PC LI was 2.5 +/- 1.8% (from 1.0 to 6.3%). In the case of PCL, circulating PC had a Ts of 14.4 hr and a LI of 3.1. From these experimental measurements, the fractional turnover rate (FTR-percentage of cells produced per unit time) and the potential doubling time (Td) of BMPC were calculated assuming that all BMPC were in a steady-state at the time of the study. BMPC FTR was 3.53 +/- 2.3% cells per day (from 1.2 to 6.72) and BMPC Td was 46.8 +/- 27.5 days (from 15.0 to 75.4). Comparison with results obtained in BM blasts of children with acute lymphoblastic leukaemia (ALL) indicated that BMPC had a lower proliferative activity (P less than 0.001), although BMPC Ts was not significantly different. In two patients a tumour doubling time of 6 and 13 months was determined by clinical follow up. Comparison of this parameter with Td showed a cell loss factor of more than 90% in both patients. Kinetic data relative to RHCP showed slight variations with respect to those found in normal subjects, with a general tendency towards a prolongation of Ts and a reduction of LI.